Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Glycomimetics Inc (GLYC)

Glycomimetics Inc (GLYC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 249,754
  • Shares Outstanding, K 43,360
  • Annual Sales, $ 0 K
  • Annual Income, $ -48,270 K
  • 60-Month Beta 2.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.35
  • Number of Estimates 5
  • High Estimate -0.34
  • Low Estimate -0.37
  • Prior Year -0.32
  • Growth Rate Est. (year over year) -9.37%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.72 +22.54%
on 11/21/19
6.72 -13.84%
on 11/15/19
-0.11 (-1.86%)
since 11/11/19
3-Month
3.95 +46.58%
on 10/02/19
6.72 -13.84%
on 11/15/19
+1.19 (+25.87%)
since 09/11/19
52-Week
2.64 +119.32%
on 08/05/19
13.56 -57.30%
on 03/27/19
-4.82 (-45.43%)
since 12/11/18

Most Recent Stories

More News
GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York,...

GLYC : 5.79 (+0.52%)
GlycoMimetics to Present at Two Upcoming Investor Conferences

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that company executives will provide a corporate update at two upcoming investor relations conferences in November. Details are as follows:

GLYC : 5.79 (+0.52%)
Pharma Sector Tops in October: Best ETFs & Stocks

Pharma sector wins in October, making these ETFs and stocks winners.

PPH : 63.02 (+0.17%)
XPH : 41.76 (+0.19%)
PJP : 64.04 (+0.08%)
ALXN : 111.71 (+0.46%)
BIIB : 297.96 (+0.26%)
ACHN : 6.20 (-0.64%)
DERM : 10.10 (+0.90%)
GLYC : 5.79 (+0.52%)
RIGL : 2.28 (+1.79%)
IRWD : 12.37 (-0.64%)
GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended September 30, 2019 and highlighted recent business developments. Quarter-end cash and cash equivalents were...

GLYC : 5.79 (+0.52%)
GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that seven abstracts covering data from the company's research and clinical portfolio have been accepted for presentation at the 61st American Society...

GLYC : 5.79 (+0.52%)
GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019

GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that it will host a conference call and webcast to report its third-quarter 2019 financial results on Thursday, November 7, 2019, at 8:30 a.m. ET.

GLYC : 5.79 (+0.52%)
GlycoMimetics to Present at Two Upcoming Investor Conferences

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at two upcoming investor relations conferences in New York, NY in September....

GLYC : 5.79 (+0.52%)
Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock?

Investors need to pay close attention to GlycoMimetics (GLYC) stock based on the movements in the options market lately.

GLYC : 5.79 (+0.52%)
GlycoMimetics Reports Top-line Results From Pfizer's Phase 3 Clinical Trial Evaluating Rivipansel in Sickle Cell Disease

GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study...

GLYC : 5.79 (+0.52%)
PFE : 38.35 (-0.34%)
GlycoMimetics Reports Second Quarter 2019 Financial Results and Recent Operational Highlights

GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the quarter ended June 30, 2019 and highlighted recent business achievements. Quarter-end cash and cash equivalents were $184.2...

GLYC : 5.79 (+0.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade GLYC with:

Business Summary

GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at...

See More

Key Turning Points

2nd Resistance Point 6.41
1st Resistance Point 6.09
Last Price 5.79
1st Support Level 5.46
2nd Support Level 5.15

See More

52-Week High 13.56
Fibonacci 61.8% 9.39
Fibonacci 50% 8.10
Fibonacci 38.2% 6.81
Last Price 5.79
52-Week Low 2.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar